跳至主要内容
临床试验/NCT05592951
NCT05592951已完成不适用

Randomized Trial to Assess the Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

University of Memphis2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年9月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Alanine transaminase

研究概览

简要总结

The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.

详细描述

Maintaining adequate hydration is essential to optimal health, as well as athletic performance. When individuals exercise (in particular in a warm environment), they can lose excessive amounts of fluids along with necessary electrolytes (e.g., sodium, potassium, chloride) through sweating. With dehydration, individuals may feel sluggish and can experience impaired physical performance.

The use of electrolytes (sodium in particular) has been used for decades to aid athlete hydration and has led to the development of various sport drinks (e.g., Gatorade, Powerade) -which also include small amounts of carbohydrate. The addition of amino acids to electrolyte solutions has previously been demonstrated to further increase the transport of water and sodium from the jejunum (small intestine). Separate research also showed an amino acid and electrolyte drink increased cellular hydration compared to flavored water and electrolyte only drinks. A 2019 study found that amino acids hydration increased beverage hydration index (BHI)-a measure of fluid balance following consumption of a beverage and was age dependent.

Amino acids supplementation has been popular for some time among athletes due to other potential performance benefits including changes to anabolic hormone levels, alterations to energy consumption, and mental endurance. Further, amino acids may reduce post-exercise muscle soreness and aid in recovery.

The electrolyte amino-acid test product is a powder provided in individual stick packs and contains L-Alanine and L-Glutamine as well as 5 essential vitamins including Vitamins B3, B5, B6, B12 and Vitamin C. It is gluten-, soy-, and dairy-free, and provides electrolytes well below the daily value. The daily value (DV) tells us how much a particular nutrient in a serving of a food product contributes to a daily diet, based on a standard 2000 calorie diet. Despite what the name suggests, this product is taken orally, not intravenously. Liquid IV packets contain: sodium (510 mg, 22%DV) and potassium (380 mg, 8%DV). These packets contain a small percentage of the needed total electrolytes but adequate amounts to replace lost electrolytes as a result of physical activity.

The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Body mass index (BMI) between 18-29.9 kg/m2
  • able to fast overnight

排除标准

  • tobacco user
  • history of heart disease/cardiovascular disease
  • hypertensive (140/90 mmHg or less)
  • history of immune disorder
  • history of kidney disease
  • hepatic impairment or disease
  • history of unstable thyroid
  • abnormality or obstruction of the gastrointestinal tract precluding swallowing
  • abnormal digestion conditions
  • previously diagnosed major affective disorder
  • psychiatric disorder that required hospitalization in prior year
  • history of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening)
  • no known sensitivity or allergy to any of the study products
  • consumption of alcohol-containing beverages within 24 hours of testing
  • consumption of caffeine-containing beverages within 24 hours of testing
  • active infection or illness of any kind
  • if female, lactating, pregnant, or planning to become pregnant during the study
  • receipt or use of an investigational product in another research study or change in medication, dietary supplementation, or significant change in diet/exercise regimen within 28 days prior to baseline/visit 2

结局指标

主要结局

Alanine transaminase

时间窗: 4 weeks of assigned treatment

Alanine transaminase measured as part of metabolic panel with units IU/L

Aspartate transferase

时间窗: 4 weeks of assigned treatment

Aspartate transferase measured as part of comprehensive metabolic panel with units IU/L

Alkaline phosphatase

时间窗: 4 weeks of assigned treatment

Alkaline phosphatase measured as part of comprehensive metabolic panel with units IU/L

chloride

时间窗: 4 weeks of assigned treatment

chloride as part of comprehensive metabolic panel with units mmol/L

potassium

时间窗: 4 weeks of assigned treatment

potassium as part of comprehensive metabolic panel with units mmol/L

sodium

时间窗: 4 weeks of assigned treatment

sodium as part of comprehensive metabolic panel with units mmol/L

blood urea nitrogen

时间窗: 4 weeks of assigned treatment

blood urea nitrogen as part of comprehensive metabolic panel with units mg/dL

calcium

时间窗: 4 weeks of assigned treatment

calcium as part of comprehensive metabolic panel with units mg/dL

total bilirubin

时间窗: 4 weeks of assigned treatment

total bilirubin measured as part of comprehensive metabolic panel with units mg/dL

blood urea nitrogen mg/dL

时间窗: baseline

blood urea nitrogen as part of comprehensive metabolic panel with unite

total protein as part of comprehensive metabolic panel with units g/dL

时间窗: 4 weeks of assigned treatment

total protein

total globulin

时间窗: 4 weeks of assigned treatment

total globulin as part of comprehensive metabolic panel with units g/dL

White blood cell distribution (absolute)

时间窗: 4 weeks of assigned treatment

absolute measures of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes per microliter as part of complete blood count panel

Red cell distribution width

时间窗: 4 weeks of assigned treatment

red cell distribution width as part of complete blood count panel with differential test measured as percentage

platelet count

时间窗: 4 weeks of assigned treatment

platelet count per microliter as part of complete blood count panel with differential test

white cell count

时间窗: 4 weeks of assigned treatment

white cell count per microliter as part of complete blood count panel with differential test

Albumin

时间窗: 4 weeks of assigned treatment

Albumin measured as part of comprehensive metabolic panel with units g/dL

carbon dioxide

时间窗: 4 weeks of assigned treatment

carbon dioxide as part of comprehensive metabolic panel with units mmol/L

blood glucose

时间窗: 4 weeks of assigned treatment

glucose as part of comprehensive metabolic panel with units mg/dL

hemoglobin

时间窗: 4 weeks of assigned treatment

hemoglobin as part of complete blood count panel with differential test measured as g/dL

Thyroxine

时间窗: 4 weeks of assigned treatment

Thyroxine ug/dL measured in blood as ug/dL

Urine potential of hydrogen

时间窗: 4 weeks of assigned treatment

Urine potential of hydrogen (pH) as reported in complete urinalysis

Protein in urine

时间窗: 4 weeks of assigned treatment

Protein, if present, measured in urine in complete urinalysis

Ketones in urine

时间窗: 4 weeks of assigned treatment

Ketones, if present, measured in urine in complete urinalysis

White blood cell esterase in urine

时间窗: 4 weeks of assigned treatment

White blood cell esterase, if present, measured in urine

Hematocrit

时间窗: 4 weeks of assigned treatment

Hematocrit as part of complete blood count panel with differential test measured as percentage

creatinine

时间窗: 4 weeks of assigned treatment

creatinine as part of comprehensive metabolic panel with units mg/dL

estimated glomerular filtration rate calculation

时间窗: 4 weeks of assigned treatment

estimated glomerular filtration rate calculation as part of comprehensive metabolic panel with units mL/min/1.73

albumin/globulin ratio

时间窗: 4 weeks of assigned treatment

albumin/globulin ratio as part of comprehensive metabolic panel

mean corpuscular hemoglobin concentration

时间窗: 4 weeks of assigned treatment

mean corpuscular hemoglobin concentration as part of complete blood count panel with differential test measured as g/dL

red cell count

时间窗: 4 weeks of assigned treatment

red cell count per microliter as part of complete blood count panel with differential test

Triiodothyronine

时间窗: 4 weeks of assigned treatment

Triiodothyronine measured in blood as ng/dL

urobilinogen in urine

时间窗: 4 weeks of assigned treatment

urobilinogen in urine measured in urinalysis as mg/dL

tolerability questionnaire

时间窗: 1 day before 4 week visit

Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)

blood urea nitrogen/creatinine ratio

时间窗: 4 weeks of assigned treatment

blood urea nitrogen/creatinine ratio as part of comprehensive metabolic panel

mean corpuscular volume

时间窗: 4 weeks of assigned treatment

mean corpuscular volume as part of complete blood count panel with differential test measured as femtoliter

White blood cell distribution (percentage)

时间窗: 4 weeks of assigned treatment

percentages of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes out of total white blood cells.

thyroid stimulating hormone

时间窗: 4 weeks of assigned treatment

Thyroxine measured in blood as micro-IU/dL

Urine appearance

时间窗: 4 weeks of assigned treatment

Urine appearance as reported in complete urinalysis

Urine specific gravity

时间窗: 4 weeks of assigned treatment

Urine specific gravity as reported in complete urinalysis

Glucose in urine

时间窗: 4 weeks of assigned treatment

Glucose, if present, measured in urine in complete urinalysis

Urine nitrite

时间窗: 4 weeks of assigned treatment

nitrite, if present, measured in urine

Heart Rate

时间窗: 4 weeks of assigned treatment

Heart rate measured using an automated blood pressure machine

Urine Color

时间窗: 4 weeks of assigned treatment

Urine color as reported in complete urinalysis

Occult blood in urine

时间窗: 4 weeks of assigned treatment

Occult blood, if present, measured in urine in complete urinalysis

bilirubin in urine

时间窗: 4 weeks of assigned treatment

bilirubin, if present, measured in urine

Blood Pressure

时间窗: 4 weeks of assigned treatment

Systolic and Diastolic blood pressure measured using an automated blood pressure machine

Product Tolerability questionnaire (gastrointestinal)

时间窗: 4 weeks of assigned treatment

Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the past two weeks from 0 (None) to 10 (severe)

Product Tolerability questionnaire (consumption)

时间窗: 4 weeks of assigned treatment visit

Questionnaire that can be scored 1-5 (1 bad quality to 5 good quality): with answers of strongly agree, agree, neutral, disagree, and strongly agree for tastes pleasant, easy to drink, easy on stomach, would purchase, dissolves easily, too gritty, too sticky and excessively, mildly too much, optimal, mildly too little, and extremely lacking for sweet, sour, salty, bitter. Final question on after taste with answers of pleasant, ok, no taste, unpleasant, extremely unpleasant.

Daily food diary

时间窗: 1 day before 4 week visit

A list of all food and drink consumed that day

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard Bloomer

Dean of the College of Health Sciences

University of Memphis

研究点 (2)

Loading locations...

相似试验